Psychosis Clinical Trial
Official title:
User-centered Design of a Mobile Health Intervention to Promote Help-seeking and Reduce Duration of Untreated Illness Among Young Adults With Early Psychosis
The proposed study research project aims to develop and test a mobile health intervention designed to improve the wellness of young people at risk for psychosis and facilitate users' engagement with treatment and thus reduce duration of untreated psychosis. This clinical trial will involve a remote pilot randomized controlled trial that will examine (1) the feasibility of the proposed research approach, (2) the acceptability and usability of the NORTH intervention as well as (3) the specific additive value of help-seeking support in the context of self-guided mHealth for early psychosis. The full intervention, which includes psychoeducational lessons, Cognitive-Behavior Therapy-based practices, a symptom tracking feature, and help-seeking resources will be compared to a "Lite" version that will include the lessons, practices, and tracking but exclude the help-seeking resources.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | April 15, 2025 |
Est. primary completion date | January 15, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion Criteria: - Elevated risk for psychosis that warrants further evaluation (a distress score >= 20 on the Prodromal Questionnaire, Brief [PQ-B], per Savill et al., 2018; and a positive frequency average score >= 1.47 on the Community Assessment of Psychic Experiences [CAPE-P15], per Jaya et al., 2021 and Bukenaite et al., 2017) and confirmation of symptoms consistent with online data collection checks (per Moritz et al., 2013) - Age 18-30 years old - Lives in the United States - Under five years since participant's first psychotic episode or awareness of symptom onset - Owns an iPhone - Unengaged in specialty mental health treatment, in which the participant has not done either of the following in the previous three months: (1) taken a prescribed antipsychotic medication, (2) attended regular (i.e. more than one session of) psychotherapy. Exclusion Criteria: - Failed to demonstrate understanding of study details in comprehension screening process. - Engaged in specialty mental health treatment in the previous three months, defined as the following: (1) taken a prescribed antipsychotic medication, OR (2) attended regular (i.e. more than one session of) psychotherapy. - Unengaged in treatment, but only as a result of having completed or "graduated" from a specialty mental health program. |
Country | Name | City | State |
---|---|---|---|
United States | University of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in treatment seeking steps | Treatment seeking will be measured using the Measure to Assess Steps to Service (MASS). The MASS is a 17-item self-report assessment of steps taken towards the attainment of mental health treatment, including research, social support, and engagement with service provider steps. Each item is endorsed on a three-point Likert scale (0 = No, I have not done this, 1 = I have done this once or twice, 2 = I have done this multiple times). The MASS is scored by summing individual items with higher scores indicating greater levels of treatment-seeking actions. | Baseline, 6 weeks, 12 weeks | |
Primary | Change in treatment-seeking attitudes | Help-Seeking Attitudes and Stigma will be measured primarily using the Endorsed and Anticipated Stigma Inventory (EASI). The EASI is a 40-item self-reported questionnaire with subscales measuring beliefs about mental illness, beliefs about mental health treatment, beliefs about mental health treatment seeking, concerns about stigma from loved ones, and concerns about stigma from the workplace. The subscales are scored by summing the ratings from the eight individual items in each subscale (5-point scale with 1 = Strongly disagree, 5 = Strongly agree), with lower scores indicating less stigma, and more positive attitudes towards treatment and treatment-seeking. | Baseline, 6 weeks, 12 weeks | |
Primary | Change in internalized stigma | The Internalized Stigma of Mental Health Inventory, Brief (ISMI-9) will provide additional insight into the strength of participants' internalized stigma of mental illness. The ISMI-9 is a nine-item self-report short form, where each item is rated on a four-point Likert scale (1 = Strongly disagree, 4 = Strongly agree), and higher scores indicate more severe internalization of mental illness stigma. | Baseline, 6 weeks, 12 weeks | |
Primary | Change in perceived stress | Perceived stress will be measured using the Perceived Stress Questionnaire (PSQ), which is a 30-item, self-report questionnaire that examines the experience of stress independent of a specific and objective occasion. Items are endorsed on a four-point scale (1 = Almost never, 4 = Usually), with higher scores indicating higher levels of perceived stress. | Baseline, 6 weeks, 12 weeks | |
Primary | Change in resilience / coping | The Brief Resilience Scale (BRS) will be used to assess resiliency. The BRS is a self-report form that consists of six resiliency statements that participants agree or disagree with on a five-point scale (1 = Strongly disagree, 5 = Strongly agree). Scores | Baseline, 6 weeks, 12 weeks | |
Secondary | Change in symptoms | The Community Assessment of Psychic Experiences (CAPE-42) will be used to assess positive, negative and general psychopathology symptoms of participants. The CAPE-42 is a self-report, 42 two-part item assessment that measures both the frequency of experiencing symptoms (four-point scale, 1 = Never, 4 = Almost Always) as well as the distress level (four-point scale, 1 = Not Distressed, 4 = Very Distressed) associated with each endorsed symptom. The CAPE is scored by summing individual frequencies and distress levels for subscales of positive symptoms, depressive symptoms, and negative symptoms, and the Distress Score is weighted by the number of symptoms experienced. | Baseline, 6 weeks, 12 weeks | |
Secondary | Change in recovery | Recovery will be assessed using the Choice of Outcome in CBT for Psychoses, Short Form (CHOICE-SF). The CHOICE-SF is an 11-item self-report form developed to assess recovery-related goals for therapy. Participants rate themselves in different therapy-focused areas such as "self-confidence" or "ways of dealing with everyday stress" on a scale (0 = Worst, 10 = Best). This will allow the study team to assess psychological changes relevant to psychosocial treatments for psychosis, which in this case is the NORTH intervention. | Baseline, 6 weeks, 12 weeks | |
Secondary | Change in functioning | Functioning will be measured using the Sheehan Disability Scale (SDS). The SDS is a short, five-item self-report form that assesses disability and functional impairment. The first three items measure to what extent symptoms have disrupted different aspects of daily life on a scale (0 = Not at all, 10 = Severely), and are followed by two items measuring presenteeism and absenteeism in the preceding week. | Baseline, 6 weeks, 12 weeks | |
Secondary | Intervention acceptability / usability | Usability/Acceptability will be assessed with a modified version of the System Usability Scale derived from our group's previous work developing mHealth interventions. This composite measure, which comprises 26 items based on four measures - the System Usability Scale, Post Study System Usability Scale, Technology Assessment Model Measurement Scales, and Usefulness, Satisfaction and Ease Questionnaire - assesses participants' experiences with the intervention during the study period. | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04929938 -
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
|
N/A | |
Recruiting |
NCT05863572 -
Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda
|
N/A | |
Completed |
NCT04277585 -
Improving Access to Early Psychosis Coordinated Specialty Care
|
N/A | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Not yet recruiting |
NCT05558332 -
Youth Nominated Support Team
|
N/A | |
Not yet recruiting |
NCT05358457 -
Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Completed |
NCT02895269 -
COllaborative Shared Care to IMprove Psychosis Outcome
|
N/A | |
Recruiting |
NCT02622048 -
Understanding and Helping Families: Parents With Psychosis
|
N/A | |
Completed |
NCT02653729 -
Cbt for Psychosis and Affect on Psychosis Symptoms
|
Phase 2 | |
Completed |
NCT02733575 -
Compassion Focused Therapy for Distressing Experiences
|
N/A | |
Completed |
NCT02531243 -
Computer-Aided Learning for Managing Stress
|
N/A | |
Not yet recruiting |
NCT02244970 -
Mindfulness RCT for Early Psychosis
|
N/A | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Withdrawn |
NCT00786318 -
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
|
Phase 4 | |
Recruiting |
NCT00722163 -
A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis
|
Phase 0 |